David E. Lazar filed a Schedule 13G with the U.S. Securities and Exchange Commission for Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) on August 15, 2025, disclosing a significant ownership position in the company.
The filing is available on the SEC's EDGAR system: